Freedom SOLO Stentless Heart Valve Study
This study is currently recruiting participants.
Verified March 2013 by Sorin Group USA, Inc.
Sponsor:
Sorin Group USA, Inc.
Information provided by (Responsible Party):
Sorin Group USA, Inc.
ClinicalTrials.gov Identifier:
NCT01115907
First received: April 29, 2010
Last updated: March 11, 2013
Last verified: March 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this clinical investigation is to demonstrate the safety and effectiveness of the Freedom SOLO heart valve.
| Condition | Intervention | Phase |
|---|---|---|
|
Aortic Stenosis Aortic Insufficiency |
Device: Freedom SOLO Stentless Heart Valve |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Clinical Investigation of the Freedom SOLO Stentless Heart Valve in North America |
Resource links provided by NLM:
Genetics Home Reference related topics:
supravalvular aortic stenosis
Drug Information available for:
Diazepam
U.S. FDA Resources
Further study details as provided by Sorin Group USA, Inc.:
Primary Outcome Measures:
- Safety will be determined by incidence rate of adverse events [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]The complication and survival rates for the SOLO valve are comparable to appropriate historical controls manifested as objective performance criteria (OPCs) and to that reported in the literature for other stentless bioprostheses and stented pericardial valves.
Secondary Outcome Measures:
- Efficacy will be determined by hemodynamics [ Time Frame: 1 year ] [ Designated as safety issue: No ]The hemodynamic performance of the SOLO valve will be compared to that reported in the literature for other stentless bioprostheses and stented pericardial valves.
- Effectiveness will be determined by NYHA Classification comparisons [ Time Frame: 1 year ] [ Designated as safety issue: No ]Clinically significant improvement in overall patient condition by comparison of preoperative and postoperative NYHA functional classifications.
| Estimated Enrollment: | 200 |
| Study Start Date: | December 2010 |
| Estimated Study Completion Date: | June 2017 |
| Estimated Primary Completion Date: | June 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Freedom SOLO stentless valve implant
Appropriate subjects will receive the Freedom SOLO stentless valve implant as a replacement for a diseased or damaged native or prosthetic aortic valve.
|
Device: Freedom SOLO Stentless Heart Valve
Freedom SOLO Stentless Heart Valve
|
Detailed Description:
The SOLO clinical investigation is a prospective, non-randomized, multicenter trial of the SOLO Freedom heart valve implanted in patients requiring aortic valve replacement.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- The subject is male or female 18 years old or older.
- The subject or subject's legal representative is willing to sign the informed consent.
- The subject which preoperative evaluation indicated the need for native or prosthetic aortic valve replacement.
- Any subject amenable to aortic valve replacement with biological prosthesis should be enrolled in the study, even in conjunction with valve repair, coronary artery bypass grafting and other procedures.
- The subject is located in a geographic location that will enable the subject to return to the study site for all follow-up examinations (i.e. geographically stable).
- Subject will be available to the investigator(s) for postoperative follow-up beyond one year.
Exclusion Criteria:
- The subject has preexisting valve prosthesis in the mitral, pulmonary or tricuspid position.
- The subject requires a double or multiple valve replacement (a valve repair is not considered an exclusion criterion).
- The subject has a previously implanted SOLO valve, within the clinical study, that requires replacement.
- The subject has active endocarditis or myocarditis.
- The subject is or will be participating in a concomitant research study of an investigational product.
- The subject is a minor, drug abuser, alcohol abuser, prison inmate, institutionalized, or is unable to give informed consent.
- The subject has a major or progressive non-cardiac disease that, in the investigator's experience, results in a life expectancy of less than 1 year, or the implant of the device produces an unacceptable increased risk to the subject.
- The subject is pregnant, planning to become pregnant or lactating.
- The subject has a congenital bicuspid aortic valve.
- The subject is known to be noncompliant or is unlikely to complete the study.
- The subject is undergoing renal dialysis for chronic renal failure or has been diagnosed with hyperparathyroidism.
- The subject has had an acute preoperative neurological deficit, myocardial infarction, or cardiac event that has not returned to baseline or stabilized ≥30 days prior to the planned valve implant surgery.
- The subject has extensive calcification of the aortic root where removal of the calcified tissue cannot be achieved.
- The subject has a significantly dilated aortic root that is not surgically corrected.
- The subject requires replacement of the aortic root / full root procedure.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01115907
Locations
| United States, California | |
| Cedars-Sinai Medical Center | Recruiting |
| Los Angeles, California, United States, 90048 | |
| Contact: Mick DeRobertis, RN 310-423-5621 Mick.deRobertis@cshs.org | |
| Principal Investigator: Ali Khoynezhad, MD | |
| United States, Georgia | |
| Emory University | Recruiting |
| Atlanta, Georgia, United States, 30308 | |
| Contact: Zachary Pitts, RN zachary.e.pitts@emory.edu | |
| Principal Investigator: Vinod Thourani, MD | |
| United States, Indiana | |
| St. Vincent Heart Center | Recruiting |
| Indianapolis, Indiana, United States, 46240 | |
| Contact: Lisa Barnett, RN 317-583-7804 lbarnett@corvascmds.com | |
| Contact: Nicole M. Toole, RN, BSN 317-583-7603 ntoole@corvascmds.com | |
| Principal Investigator: David Heimansohn, MD | |
| United States, Michigan | |
| Oakwood Hospital | Recruiting |
| Dearborn, Michigan, United States, 48124 | |
| Contact: Lynne Meharg, RN, BSN 313-982-5376 mehargl@oakwood.org | |
| Principal Investigator: Reza Dabir, MD | |
| United States, New Jersey | |
| The Valley Hospital | Recruiting |
| Ridgewood, New Jersey, United States, 07450 | |
| Contact: Kathleen Sayles, RN, BSN, 201-447-8338 ksayles@valleyhealth.com | |
| Principal Investigator: Alex Zapolanski, MD | |
| United States, Ohio | |
| Cleveland Clinic Foundation | Recruiting |
| Cleveland, Ohio, United States, 44195 | |
| Contact: Roberta Palumbo, RN 216-444-8774 palumbor@ccf.org | |
| Principal Investigator: Eric Roselli, MD | |
| The Toledo Hospital | Recruiting |
| Toledo, Ohio, United States, 43606 | |
| Contact: Melanie Wheeler, RN, BSN 419-291-3699 Melanie.Wheeler@ProMedica.org | |
| Principal Investigator: Michael Moront, MD | |
| United States, Pennsylvania | |
| Hospital of the University of Pennsylvania | Recruiting |
| Philadelphia, Pennsylvania, United States, 19104 | |
| Contact: Rohan Menon Rohan.Menon@uphs.upenn.edu | |
| Principal Investigator: Prashanth Vallabhajosyula, MD | |
| Lankenau Medical Center | Recruiting |
| Wynnewood, Pennsylvania, United States, 19096 | |
| Contact: Susan Herring, RN, M.Ed 484-476-8514 herrings@mlhs.org | |
| Principal Investigator: Scott Goldman, MD | |
| Canada, Alberta | |
| Foothills Medical Centre | Active, not recruiting |
| Calgary, Alberta, Canada, T2N 2T9 | |
| University of Alberta Hospital | Active, not recruiting |
| Edmonton, Alberta, Canada, T6G 2B7 | |
| Canada, British Columbia | |
| University of Bristish Columbia St. Paul Hospital | Active, not recruiting |
| Vancouver, British Columbia, Canada | |
| Canada, Manitoba | |
| St. Boniface Hospital | Active, not recruiting |
| Winnipeg, Manitoba, Canada | |
| Canada, Ontario | |
| London Health Sciences Centre | Active, not recruiting |
| London, Ontario, Canada | |
| Canada | |
| Institut Universitaire de Cardiologie et de Pneumologie de Québec | Active, not recruiting |
| Quebec, Canada, G1V 4G5 | |
Sponsors and Collaborators
Sorin Group USA, Inc.
Investigators
| Principal Investigator: | Eric Roselli, M.D. | The Cleveland Clinic |
| Principal Investigator: | David Heimansohn, MD | St. Vincent Heart Center |
| Principal Investigator: | Alex Zapolanski, MD | The Valley Hospital |
| Principal Investigator: | Vinod Thourani, MD | Emory University |
| Principal Investigator: | Reza Dabir, MD | Oakwood Hospital |
| Principal Investigator: | Ali Khoynezhad, MD | Cedars-Sinai Medical Center |
| Principal Investigator: | Pranshanth Vallabhajosyula, MD | University of Pennsylvania |
| Principal Investigator: | Michael Moront, MD | The Toledo Hospital |
| Principal Investigator: | Scott Goldman, MD | Main Line Health |
| Principal Investigator: | Shaohua Wang, MD | University of Alberta |
| Principal Investigator: | L. Ray Guo, MD | London Health Science Centre |
| Principal Investigator: | Andrew Maitland, MD | Foothills Medical Center |
| Principal Investigator: | Michael Moon, MD | St. Boniface Hospital |
| Principal Investigator: | Pierre Voisine, MD | Institut Universitaire de Cardiologie et de Pneumologie de Québec |
| Principal Investigator: | Jian Ye, MD | St. Paul's Hospital |
More Information
No publications provided
| Responsible Party: | Sorin Group USA, Inc. |
| ClinicalTrials.gov Identifier: | NCT01115907 History of Changes |
| Other Study ID Numbers: | G100014 |
| Study First Received: | April 29, 2010 |
| Last Updated: | March 11, 2013 |
| Health Authority: | United States: Food and Drug Administration Canada: Health Canada |
Keywords provided by Sorin Group USA, Inc.:
|
Aortic Valve replacement |
Additional relevant MeSH terms:
|
Aortic Valve Insufficiency Aortic Valve Stenosis Heart Valve Diseases Heart Diseases Cardiovascular Diseases Ventricular Outflow Obstruction Diazepam Anticonvulsants Central Nervous System Agents Therapeutic Uses Pharmacologic Actions Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs |
Gastrointestinal Agents Hypnotics and Sedatives Central Nervous System Depressants Muscle Relaxants, Central Neuromuscular Agents Anti-Anxiety Agents Tranquilizing Agents Psychotropic Drugs Anesthetics, Intravenous Anesthetics, General Anesthetics GABA Modulators GABA Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on June 18, 2013